| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Atrial Fibrillation | 22 | 2022 | 249 | 5.390 |
Why?
|
| Catheter Ablation | 24 | 2022 | 229 | 4.320 |
Why?
|
| Tachycardia, Ventricular | 14 | 2022 | 153 | 3.100 |
Why?
|
| Death, Sudden, Cardiac | 12 | 2020 | 141 | 1.990 |
Why?
|
| Anti-Arrhythmia Agents | 9 | 2021 | 98 | 1.950 |
Why?
|
| Cardiology | 15 | 2019 | 140 | 1.810 |
Why?
|
| Heart Conduction System | 6 | 2018 | 119 | 1.580 |
Why?
|
| Electrocardiography | 18 | 2022 | 601 | 1.560 |
Why?
|
| Cardiac Resynchronization Therapy | 7 | 2022 | 119 | 1.440 |
Why?
|
| Electric Countershock | 9 | 2020 | 130 | 1.410 |
Why?
|
| American Heart Association | 15 | 2019 | 142 | 1.410 |
Why?
|
| Defibrillators, Implantable | 9 | 2020 | 329 | 1.390 |
Why?
|
| Arrhythmias, Cardiac | 6 | 2018 | 239 | 1.330 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 10 | 2018 | 61 | 1.310 |
Why?
|
| Tachycardia, Supraventricular | 8 | 2022 | 73 | 1.240 |
Why?
|
| Heart Failure | 9 | 2022 | 1180 | 1.240 |
Why?
|
| Echocardiography | 5 | 2020 | 515 | 1.230 |
Why?
|
| Heart Rate | 4 | 2019 | 568 | 1.160 |
Why?
|
| Pacemaker, Artificial | 5 | 2017 | 157 | 1.060 |
Why?
|
| Atrioventricular Block | 2 | 2016 | 5 | 1.040 |
Why?
|
| Atrioventricular Node | 2 | 2018 | 39 | 1.030 |
Why?
|
| Ventricular Function, Left | 4 | 2020 | 481 | 0.900 |
Why?
|
| Bundle-Branch Block | 4 | 2021 | 50 | 0.890 |
Why?
|
| Humans | 86 | 2022 | 68618 | 0.840 |
Why?
|
| Defibrillators | 4 | 2018 | 11 | 0.820 |
Why?
|
| Treatment Outcome | 21 | 2022 | 7029 | 0.810 |
Why?
|
| Sotalol | 1 | 2021 | 6 | 0.810 |
Why?
|
| Action Potentials | 3 | 2019 | 223 | 0.750 |
Why?
|
| Ventricular Premature Complexes | 4 | 2022 | 10 | 0.720 |
Why?
|
| Heart Ventricles | 5 | 2022 | 738 | 0.720 |
Why?
|
| Heart Atria | 5 | 2022 | 206 | 0.700 |
Why?
|
| Aged | 27 | 2022 | 14862 | 0.670 |
Why?
|
| Registries | 2 | 2021 | 733 | 0.650 |
Why?
|
| Wearable Electronic Devices | 1 | 2018 | 16 | 0.630 |
Why?
|
| Decision Support Techniques | 2 | 2019 | 191 | 0.630 |
Why?
|
| Tachycardia, Sinus | 1 | 2018 | 4 | 0.630 |
Why?
|
| Guideline Adherence | 1 | 2021 | 287 | 0.630 |
Why?
|
| Sinoatrial Node | 1 | 2018 | 14 | 0.620 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2017 | 34 | 0.600 |
Why?
|
| Pregnancy Complications, Cardiovascular | 3 | 2015 | 34 | 0.590 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2017 | 33 | 0.590 |
Why?
|
| Ventricular Remodeling | 2 | 2019 | 318 | 0.580 |
Why?
|
| Practice Guidelines as Topic | 6 | 2019 | 772 | 0.560 |
Why?
|
| Ventricular Fibrillation | 4 | 2020 | 85 | 0.550 |
Why?
|
| Syncope | 1 | 2016 | 23 | 0.550 |
Why?
|
| Heart Arrest | 1 | 2017 | 113 | 0.540 |
Why?
|
| Societies, Medical | 5 | 2019 | 403 | 0.530 |
Why?
|
| Baroreflex | 1 | 2016 | 20 | 0.530 |
Why?
|
| Cardiac Pacing, Artificial | 2 | 2007 | 174 | 0.530 |
Why?
|
| Middle Aged | 31 | 2022 | 21147 | 0.520 |
Why?
|
| Electronic Health Records | 1 | 2019 | 374 | 0.520 |
Why?
|
| Female | 42 | 2021 | 38074 | 0.520 |
Why?
|
| Male | 38 | 2021 | 37321 | 0.510 |
Why?
|
| Advisory Committees | 6 | 2019 | 73 | 0.440 |
Why?
|
| Risk Factors | 14 | 2020 | 5731 | 0.440 |
Why?
|
| Myocardial Infarction | 1 | 2018 | 807 | 0.430 |
Why?
|
| Intellectual Disability | 3 | 2021 | 114 | 0.430 |
Why?
|
| Evidence-Based Medicine | 7 | 2018 | 438 | 0.420 |
Why?
|
| Disease Management | 6 | 2019 | 248 | 0.390 |
Why?
|
| Vagus Nerve Stimulation | 1 | 2012 | 61 | 0.390 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2022 | 59 | 0.390 |
Why?
|
| Retrospective Studies | 17 | 2022 | 7277 | 0.380 |
Why?
|
| Crohn Disease | 2 | 2022 | 38 | 0.380 |
Why?
|
| Time Factors | 8 | 2020 | 4655 | 0.360 |
Why?
|
| Intestines | 3 | 2022 | 114 | 0.360 |
Why?
|
| United States | 20 | 2020 | 7367 | 0.360 |
Why?
|
| Electrodes, Implanted | 2 | 2007 | 98 | 0.350 |
Why?
|
| Geologic Sediments | 2 | 2010 | 75 | 0.350 |
Why?
|
| Prosthesis Implantation | 3 | 2020 | 83 | 0.340 |
Why?
|
| Immunophenotyping | 2 | 2020 | 110 | 0.330 |
Why?
|
| Wisconsin | 3 | 2018 | 31 | 0.330 |
Why?
|
| Young Adult | 11 | 2021 | 5717 | 0.310 |
Why?
|
| Cardiac Output, Low | 2 | 2014 | 52 | 0.300 |
Why?
|
| Hypertension | 1 | 2017 | 1535 | 0.300 |
Why?
|
| Heart-Assist Devices | 3 | 2020 | 221 | 0.300 |
Why?
|
| Decision Making | 6 | 2019 | 410 | 0.300 |
Why?
|
| Recurrence | 3 | 2021 | 948 | 0.290 |
Why?
|
| Adult | 21 | 2021 | 21403 | 0.290 |
Why?
|
| Risk Assessment | 5 | 2019 | 2007 | 0.290 |
Why?
|
| Stroke Volume | 4 | 2018 | 586 | 0.280 |
Why?
|
| Anthozoa | 1 | 2006 | 5 | 0.270 |
Why?
|
| Cost-Benefit Analysis | 5 | 2017 | 504 | 0.270 |
Why?
|
| Surgical Procedures, Operative | 1 | 2007 | 124 | 0.270 |
Why?
|
| Brugada Syndrome | 3 | 2013 | 5 | 0.270 |
Why?
|
| Specimen Handling | 1 | 2006 | 47 | 0.270 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2006 | 117 | 0.250 |
Why?
|
| Case-Control Studies | 3 | 2020 | 1553 | 0.250 |
Why?
|
| Environmental Monitoring | 1 | 2006 | 180 | 0.240 |
Why?
|
| Clinical Competence | 4 | 2017 | 657 | 0.240 |
Why?
|
| Secondary Prevention | 4 | 2020 | 291 | 0.230 |
Why?
|
| Proportional Hazards Models | 2 | 2021 | 792 | 0.230 |
Why?
|
| Patient Selection | 1 | 2007 | 592 | 0.220 |
Why?
|
| Consensus | 3 | 2018 | 211 | 0.210 |
Why?
|
| Exome | 1 | 2022 | 20 | 0.210 |
Why?
|
| Qa-SNARE Proteins | 1 | 2021 | 5 | 0.200 |
Why?
|
| Immune System Diseases | 1 | 2021 | 12 | 0.200 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2021 | 161 | 0.200 |
Why?
|
| Predictive Value of Tests | 3 | 2021 | 1465 | 0.200 |
Why?
|
| Administration, Intravenous | 1 | 2021 | 89 | 0.200 |
Why?
|
| Procainamide | 1 | 2021 | 12 | 0.190 |
Why?
|
| Follow-Up Studies | 5 | 2021 | 3259 | 0.190 |
Why?
|
| Loss of Function Mutation | 1 | 2021 | 12 | 0.190 |
Why?
|
| Language Development Disorders | 1 | 2021 | 9 | 0.190 |
Why?
|
| Craniofacial Abnormalities | 1 | 2021 | 18 | 0.190 |
Why?
|
| Intestinal Mucosa | 2 | 2020 | 219 | 0.190 |
Why?
|
| Heterozygote | 1 | 2021 | 174 | 0.190 |
Why?
|
| Fragile X Syndrome | 1 | 2020 | 17 | 0.180 |
Why?
|
| Mosaicism | 1 | 2020 | 21 | 0.180 |
Why?
|
| Adolescent | 8 | 2021 | 8912 | 0.180 |
Why?
|
| Blood Pressure | 2 | 2017 | 1451 | 0.180 |
Why?
|
| Pregnancy | 5 | 2018 | 2334 | 0.180 |
Why?
|
| Fragile X Mental Retardation Protein | 1 | 2020 | 20 | 0.180 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2021 | 110 | 0.180 |
Why?
|
| Immunity, Cellular | 1 | 2020 | 80 | 0.180 |
Why?
|
| Colitis, Ulcerative | 1 | 2020 | 53 | 0.170 |
Why?
|
| Electromagnetic Fields | 1 | 2020 | 66 | 0.170 |
Why?
|
| Alleles | 1 | 2020 | 386 | 0.170 |
Why?
|
| Prosthesis Failure | 1 | 2020 | 130 | 0.170 |
Why?
|
| RNA-Binding Proteins | 1 | 2021 | 215 | 0.170 |
Why?
|
| Heart Transplantation | 2 | 2016 | 328 | 0.160 |
Why?
|
| STAT1 Transcription Factor | 1 | 2019 | 35 | 0.160 |
Why?
|
| Patient Discharge | 1 | 2021 | 294 | 0.160 |
Why?
|
| Workflow | 1 | 2019 | 100 | 0.160 |
Why?
|
| Death, Sudden | 1 | 2018 | 24 | 0.160 |
Why?
|
| Killer Cells, Natural | 1 | 2019 | 94 | 0.160 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2019 | 37 | 0.160 |
Why?
|
| Italy | 1 | 2018 | 36 | 0.160 |
Why?
|
| Kidney Failure, Chronic | 1 | 2021 | 365 | 0.150 |
Why?
|
| Patient Participation | 1 | 2019 | 146 | 0.150 |
Why?
|
| Urinary Catheterization | 1 | 2018 | 27 | 0.150 |
Why?
|
| Emergency Service, Hospital | 2 | 2021 | 711 | 0.150 |
Why?
|
| Neurocognitive Disorders | 1 | 2017 | 23 | 0.150 |
Why?
|
| Cryopreservation | 1 | 2018 | 103 | 0.150 |
Why?
|
| Clinical Protocols | 1 | 2018 | 172 | 0.150 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2018 | 62 | 0.150 |
Why?
|
| Catheter-Related Infections | 1 | 2018 | 43 | 0.150 |
Why?
|
| Colitis | 1 | 2019 | 156 | 0.150 |
Why?
|
| Electrophysiology | 2 | 2015 | 160 | 0.150 |
Why?
|
| Injections | 1 | 2017 | 119 | 0.150 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2019 | 226 | 0.150 |
Why?
|
| Accessory Atrioventricular Bundle | 1 | 2017 | 2 | 0.150 |
Why?
|
| Tachycardia, Atrioventricular Nodal Reentry | 1 | 2017 | 12 | 0.150 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 1 | 2017 | 11 | 0.140 |
Why?
|
| Patient Readmission | 1 | 2019 | 267 | 0.140 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2018 | 171 | 0.140 |
Why?
|
| Algorithms | 3 | 2018 | 1196 | 0.140 |
Why?
|
| Databases, Factual | 1 | 2019 | 622 | 0.140 |
Why?
|
| Ultrasonography, Interventional | 1 | 2017 | 119 | 0.140 |
Why?
|
| Catheterization, Central Venous | 1 | 2017 | 89 | 0.140 |
Why?
|
| Fumarate Hydratase | 1 | 2016 | 2 | 0.140 |
Why?
|
| Leiomyomatosis | 1 | 2016 | 3 | 0.140 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2017 | 72 | 0.140 |
Why?
|
| Genetic Counseling | 1 | 2016 | 45 | 0.140 |
Why?
|
| Machine Learning | 1 | 2018 | 170 | 0.130 |
Why?
|
| Utah | 1 | 2016 | 27 | 0.130 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2020 | 468 | 0.130 |
Why?
|
| Ambulatory Care | 1 | 2018 | 340 | 0.130 |
Why?
|
| RNA, Messenger | 1 | 2020 | 1664 | 0.130 |
Why?
|
| Arrestins | 3 | 2001 | 92 | 0.130 |
Why?
|
| Uterine Neoplasms | 1 | 2016 | 99 | 0.130 |
Why?
|
| Research Design | 1 | 2020 | 729 | 0.130 |
Why?
|
| Asthma | 1 | 2020 | 345 | 0.130 |
Why?
|
| Cardiac Electrophysiology | 1 | 2015 | 2 | 0.130 |
Why?
|
| Aged, 80 and over | 3 | 2020 | 4848 | 0.130 |
Why?
|
| Mitogen-Activated Protein Kinases | 3 | 2001 | 250 | 0.130 |
Why?
|
| Prospective Studies | 3 | 2020 | 3705 | 0.130 |
Why?
|
| Risk Adjustment | 1 | 2015 | 49 | 0.130 |
Why?
|
| Patient Care Management | 1 | 2015 | 40 | 0.130 |
Why?
|
| Pregnancy Outcome | 1 | 2015 | 157 | 0.120 |
Why?
|
| Islands | 1 | 2014 | 3 | 0.120 |
Why?
|
| Histone Demethylases | 1 | 2015 | 22 | 0.120 |
Why?
|
| Cohort Studies | 4 | 2020 | 2358 | 0.120 |
Why?
|
| Global Warming | 1 | 2014 | 4 | 0.120 |
Why?
|
| Education, Medical, Continuing | 1 | 2015 | 136 | 0.120 |
Why?
|
| Phenotype | 4 | 2022 | 947 | 0.120 |
Why?
|
| Health Care Costs | 1 | 2017 | 346 | 0.120 |
Why?
|
| Mutation | 3 | 2016 | 1213 | 0.120 |
Why?
|
| Primary Prevention | 3 | 2020 | 115 | 0.110 |
Why?
|
| Primary Health Care | 1 | 2019 | 703 | 0.110 |
Why?
|
| Incidence | 3 | 2020 | 1603 | 0.110 |
Why?
|
| Child | 7 | 2021 | 6405 | 0.110 |
Why?
|
| DNA-Binding Proteins | 1 | 2017 | 700 | 0.110 |
Why?
|
| Education, Medical, Graduate | 1 | 2015 | 214 | 0.110 |
Why?
|
| Antihypertensive Agents | 1 | 2017 | 498 | 0.110 |
Why?
|
| Heart Diseases | 1 | 2015 | 276 | 0.110 |
Why?
|
| Exercise Test | 2 | 2017 | 242 | 0.110 |
Why?
|
| Lung Neoplasms | 1 | 2021 | 1173 | 0.110 |
Why?
|
| Child, Preschool | 5 | 2021 | 3187 | 0.100 |
Why?
|
| Recovery of Function | 1 | 2016 | 506 | 0.100 |
Why?
|
| Quality of Life | 5 | 2020 | 1515 | 0.100 |
Why?
|
| Biomarkers, Tumor | 1 | 2016 | 508 | 0.100 |
Why?
|
| Skin Neoplasms | 1 | 2016 | 375 | 0.100 |
Why?
|
| Age of Onset | 2 | 2022 | 188 | 0.100 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2012 | 189 | 0.100 |
Why?
|
| Comorbidity | 4 | 2018 | 1426 | 0.100 |
Why?
|
| Cicatrix | 1 | 2011 | 60 | 0.090 |
Why?
|
| Coral Reefs | 1 | 2010 | 2 | 0.090 |
Why?
|
| Hawaii | 2 | 2010 | 24 | 0.090 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2001 | 195 | 0.090 |
Why?
|
| Barium | 1 | 2010 | 52 | 0.090 |
Why?
|
| Animals | 8 | 2019 | 20881 | 0.090 |
Why?
|
| Prosthesis Design | 2 | 2020 | 301 | 0.080 |
Why?
|
| Syndrome | 2 | 2021 | 255 | 0.080 |
Why?
|
| Autopsy | 2 | 2018 | 56 | 0.080 |
Why?
|
| Prognosis | 4 | 2016 | 2093 | 0.080 |
Why?
|
| Terminal Care | 2 | 2018 | 92 | 0.070 |
Why?
|
| Myocardial Ischemia | 1 | 2008 | 172 | 0.070 |
Why?
|
| Breast Neoplasms | 1 | 2016 | 1536 | 0.070 |
Why?
|
| Retreatment | 1 | 2006 | 59 | 0.070 |
Why?
|
| Reference Values | 2 | 2018 | 579 | 0.070 |
Why?
|
| Cardiomyopathies | 1 | 2008 | 167 | 0.070 |
Why?
|
| Artifacts | 1 | 2007 | 125 | 0.070 |
Why?
|
| Thromboembolism | 2 | 2019 | 91 | 0.070 |
Why?
|
| Calcium | 1 | 2010 | 929 | 0.070 |
Why?
|
| Water Pollutants, Chemical | 1 | 2010 | 328 | 0.070 |
Why?
|
| Magnetics | 1 | 2006 | 52 | 0.070 |
Why?
|
| Cardiovascular Diseases | 3 | 2018 | 940 | 0.070 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 2 | 2015 | 11 | 0.070 |
Why?
|
| Bacterial Infections | 1 | 2007 | 163 | 0.060 |
Why?
|
| Particle Size | 1 | 2006 | 201 | 0.060 |
Why?
|
| Metals | 1 | 2006 | 100 | 0.060 |
Why?
|
| Cardiovascular Agents | 2 | 2015 | 82 | 0.060 |
Why?
|
| Survival Analysis | 1 | 2006 | 714 | 0.060 |
Why?
|
| Hospitalization | 2 | 2021 | 978 | 0.060 |
Why?
|
| Feasibility Studies | 2 | 2017 | 652 | 0.060 |
Why?
|
| Infant | 3 | 2021 | 2891 | 0.060 |
Why?
|
| Combined Modality Therapy | 2 | 2015 | 951 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2007 | 848 | 0.050 |
Why?
|
| Whole Genome Sequencing | 1 | 2022 | 7 | 0.050 |
Why?
|
| Centromere | 1 | 2002 | 15 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2002 | 18 | 0.050 |
Why?
|
| Epicardial Mapping | 1 | 2022 | 4 | 0.050 |
Why?
|
| Signal Transduction | 3 | 2021 | 2689 | 0.050 |
Why?
|
| Cardiac Resynchronization Therapy Devices | 1 | 2022 | 22 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2007 | 1330 | 0.050 |
Why?
|
| Chromosome Mapping | 1 | 2022 | 188 | 0.050 |
Why?
|
| Chromosome Aberrations | 1 | 2002 | 86 | 0.050 |
Why?
|
| Endocardium | 1 | 2022 | 101 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2022 | 2324 | 0.050 |
Why?
|
| Pericardium | 1 | 2022 | 97 | 0.050 |
Why?
|
| Arabidopsis Proteins | 1 | 2001 | 13 | 0.050 |
Why?
|
| Haploinsufficiency | 1 | 2021 | 14 | 0.050 |
Why?
|
| Pedigree | 1 | 2021 | 159 | 0.050 |
Why?
|
| Ethanol | 1 | 2007 | 893 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2006 | 1851 | 0.050 |
Why?
|
| Diagnosis, Differential | 2 | 2017 | 1140 | 0.050 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2000 | 33 | 0.050 |
Why?
|
| Epidermal Growth Factor | 1 | 2001 | 95 | 0.050 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2000 | 34 | 0.050 |
Why?
|
| Receptors, Angiotensin | 1 | 2000 | 59 | 0.050 |
Why?
|
| Infusions, Intravenous | 1 | 2021 | 334 | 0.050 |
Why?
|
| Base Sequence | 1 | 2022 | 1015 | 0.050 |
Why?
|
| Trinucleotide Repeat Expansion | 1 | 2020 | 5 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2021 | 220 | 0.050 |
Why?
|
| Chile | 1 | 2020 | 17 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2001 | 150 | 0.050 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 159 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2020 | 35 | 0.040 |
Why?
|
| Heparin | 1 | 2001 | 205 | 0.040 |
Why?
|
| GTP-Binding Proteins | 1 | 2001 | 231 | 0.040 |
Why?
|
| Gene Silencing | 1 | 2020 | 137 | 0.040 |
Why?
|
| Electric Impedance | 1 | 2020 | 131 | 0.040 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2020 | 209 | 0.040 |
Why?
|
| Australia | 1 | 2020 | 235 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 1 | 2000 | 247 | 0.040 |
Why?
|
| ErbB Receptors | 1 | 2001 | 239 | 0.040 |
Why?
|
| Colon | 1 | 2020 | 168 | 0.040 |
Why?
|
| Enzyme Activation | 4 | 2001 | 791 | 0.040 |
Why?
|
| Flow Cytometry | 1 | 2020 | 489 | 0.040 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2019 | 24 | 0.040 |
Why?
|
| Atrial Flutter | 1 | 2018 | 16 | 0.040 |
Why?
|
| DNA Methylation | 1 | 2020 | 193 | 0.040 |
Why?
|
| Research Report | 1 | 2019 | 35 | 0.040 |
Why?
|
| Adoptive Transfer | 1 | 2019 | 100 | 0.040 |
Why?
|
| Athletes | 1 | 2018 | 40 | 0.040 |
Why?
|
| Mandibulofacial Dysostosis | 1 | 2017 | 3 | 0.040 |
Why?
|
| Peripheral Nervous System | 1 | 2017 | 12 | 0.040 |
Why?
|
| Codon, Nonsense | 1 | 2017 | 15 | 0.040 |
Why?
|
| Limb Deformities, Congenital | 1 | 2017 | 12 | 0.040 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2019 | 216 | 0.040 |
Why?
|
| Hospitals, University | 1 | 2018 | 169 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 68 | 0.040 |
Why?
|
| Vascular Access Devices | 1 | 2017 | 21 | 0.040 |
Why?
|
| Body Surface Potential Mapping | 1 | 2017 | 10 | 0.040 |
Why?
|
| Medical History Taking | 1 | 2017 | 94 | 0.040 |
Why?
|
| Central Nervous System | 1 | 2017 | 107 | 0.040 |
Why?
|
| Physical Examination | 1 | 2017 | 152 | 0.040 |
Why?
|
| beta-Arrestins | 3 | 2001 | 80 | 0.040 |
Why?
|
| BRCA2 Protein | 1 | 2016 | 18 | 0.040 |
Why?
|
| COS Cells | 3 | 2001 | 155 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2021 | 454 | 0.040 |
Why?
|
| Germ-Line Mutation | 1 | 2016 | 43 | 0.030 |
Why?
|
| BRCA1 Protein | 1 | 2016 | 30 | 0.030 |
Why?
|
| Prevalence | 2 | 2013 | 1619 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 1054 | 0.030 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2016 | 14 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2016 | 53 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 498 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2018 | 383 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2018 | 275 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2016 | 159 | 0.030 |
Why?
|
| Health Planning Guidelines | 1 | 2015 | 23 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2021 | 2455 | 0.030 |
Why?
|
| Credentialing | 1 | 2015 | 23 | 0.030 |
Why?
|
| Mortality | 1 | 2016 | 163 | 0.030 |
Why?
|
| Cell Survival | 1 | 2018 | 901 | 0.030 |
Why?
|
| Patient Safety | 1 | 2017 | 202 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2016 | 159 | 0.030 |
Why?
|
| Genes, X-Linked | 1 | 2015 | 6 | 0.030 |
Why?
|
| Enzyme Stability | 1 | 2015 | 30 | 0.030 |
Why?
|
| Education | 1 | 2015 | 83 | 0.030 |
Why?
|
| Methylation | 1 | 2015 | 56 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2015 | 67 | 0.030 |
Why?
|
| Europe | 1 | 2015 | 196 | 0.030 |
Why?
|
| Sex Factors | 1 | 2018 | 1266 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2019 | 1034 | 0.030 |
Why?
|
| Chromatin | 1 | 2015 | 76 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2019 | 1692 | 0.030 |
Why?
|
| Fellowships and Scholarships | 1 | 2015 | 127 | 0.030 |
Why?
|
| Self Report | 1 | 2016 | 371 | 0.030 |
Why?
|
| Biomarkers | 1 | 2020 | 1593 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2016 | 880 | 0.030 |
Why?
|
| Histones | 1 | 2015 | 111 | 0.030 |
Why?
|
| Autonomic Nervous System | 1 | 2014 | 31 | 0.030 |
Why?
|
| Septal Occluder Device | 1 | 2014 | 21 | 0.030 |
Why?
|
| Evidence-Based Practice | 1 | 2015 | 146 | 0.030 |
Why?
|
| Renin-Angiotensin System | 1 | 2014 | 79 | 0.030 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2014 | 101 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2019 | 2673 | 0.030 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2014 | 100 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 1174 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2014 | 180 | 0.030 |
Why?
|
| Heart | 1 | 2017 | 850 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 786 | 0.030 |
Why?
|
| Stroke | 2 | 2016 | 2163 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 2791 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 536 | 0.030 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2014 | 373 | 0.020 |
Why?
|
| Curriculum | 1 | 2015 | 575 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 10 | 2 | 2001 | 8 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2014 | 356 | 0.020 |
Why?
|
| beta-Arrestin 2 | 2 | 2001 | 29 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 2 | 2001 | 82 | 0.020 |
Why?
|
| Fibrinolytic Agents | 1 | 2014 | 377 | 0.020 |
Why?
|
| Pacific Ocean | 1 | 2010 | 10 | 0.020 |
Why?
|
| Mice | 2 | 2019 | 8474 | 0.020 |
Why?
|
| Angiotensin II | 2 | 2001 | 220 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2014 | 718 | 0.020 |
Why?
|
| France | 1 | 2008 | 26 | 0.020 |
Why?
|
| Protein Binding | 2 | 2001 | 1027 | 0.020 |
Why?
|
| Phosphorylation | 2 | 2001 | 1200 | 0.020 |
Why?
|
| Inflammation | 1 | 2014 | 1030 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2008 | 274 | 0.020 |
Why?
|
| Logistic Models | 1 | 2011 | 1420 | 0.020 |
Why?
|
| Equipment Failure | 1 | 2007 | 112 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 1753 | 0.020 |
Why?
|
| Equipment Failure Analysis | 1 | 2007 | 121 | 0.020 |
Why?
|
| Cell Line | 2 | 2001 | 1752 | 0.020 |
Why?
|
| Survival Rate | 1 | 2008 | 1056 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2002 | 95 | 0.010 |
Why?
|
| Karyotyping | 1 | 2002 | 74 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2002 | 144 | 0.010 |
Why?
|
| Abnormalities, Multiple | 1 | 2002 | 109 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 2001 | 88 | 0.010 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2001 | 34 | 0.010 |
Why?
|
| Plant Proteins | 1 | 2001 | 48 | 0.010 |
Why?
|
| Amino Acid Motifs | 1 | 2001 | 77 | 0.010 |
Why?
|
| MAP Kinase Kinase Kinase 5 | 1 | 2000 | 1 | 0.010 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2000 | 28 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2001 | 231 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 2001 | 147 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2000 | 71 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2001 | 254 | 0.010 |
Why?
|
| Endosomes | 1 | 2000 | 45 | 0.010 |
Why?
|
| Cytosol | 1 | 2000 | 123 | 0.010 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2000 | 80 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2001 | 322 | 0.010 |
Why?
|
| Plasmids | 1 | 2001 | 258 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 2001 | 337 | 0.010 |
Why?
|
| Genotype | 1 | 2002 | 786 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2000 | 305 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2000 | 376 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2001 | 1083 | 0.010 |
Why?
|
| Transfection | 1 | 2000 | 782 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2001 | 1447 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2001 | 1745 | 0.010 |
Why?
|
| Models, Biological | 1 | 2001 | 981 | 0.010 |
Why?
|
| Rats | 1 | 2000 | 5300 | 0.010 |
Why?
|